| Name | Title | Contact Details |
|---|
National Hospital Specialties is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women`s health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has over 8,000 employees with products sold in over 100 countries.
Martab Physicians Hospital Supply Co. is a Mahwah, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GDM's VACS software provides capture capabilities and collaborative tools using typically un-captured but critical visual information between patients, clinicians and medical specialists. VACS helps solve the problems today’s clinicians face relating to increased patient flow, less time available and increased demand for better outcomes. The VACS platform, which includes proprietary management software, digital capture/streaming and mobile applications, provides a new level of “rich media” capture, access, interaction and use of images, video, audio and other data elements. Management is currently focused on expanding the VACS platform internationally, to increase clinical efficiency and bridge the visual information gap in today’s growing clinical collaboration processes
Founded in 1998, REVA Medical is dedicated to developing minimally invasive medical devices that leverage its proprietary biomaterial and stent technologies to improve the treatment of coronary artery disease. Guided by an executive management team and scientific advisors with extensive product development and clinical interventional cardiology experience, REVA’s initial focus is the development of a drug-eluting bioresorbable coronary scaffold to advance the treatment of cardiovascular disease, the leading cause of death worldwide.